Compare NSP & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSP | NKTR |
|---|---|---|
| Founded | 1986 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 1996 | 1996 |
| Metric | NSP | NKTR |
|---|---|---|
| Price | $48.75 | $39.60 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 14 |
| Target Price | $51.75 | ★ $133.36 |
| AVG Volume (30 Days) | 434.2K | ★ 1.7M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 4.92% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | ★ $6,812,000,000.00 | $307,711,000.00 |
| Revenue This Year | $1.40 | N/A |
| Revenue Next Year | $4.27 | $30.00 |
| P/E Ratio | $49.85 | ★ N/A |
| Revenue Growth | 3.51 | ★ 86.00 |
| 52 Week Low | $18.57 | $33.40 |
| 52 Week High | $55.90 | $109.00 |
| Indicator | NSP | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 48.75 | 22.47 |
| Support Level | $47.12 | $33.87 |
| Resistance Level | $55.04 | $76.63 |
| Average True Range (ATR) | 1.93 | 3.40 |
| MACD | 0.16 | -1.42 |
| Stochastic Oscillator | 60.42 | 5.14 |
Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.